Organon To Report Third Quarter Results and Host Conference Call on November 11, 2021

Rhea-AI Summary

Organon (NYSE: OGN) will release its third quarter 2021 financial results on November 11, 2021, before a webcast and conference call at 8:30 a.m. ET. Interested parties can access the live call via the Organon website, with a replay available two hours post-event. Institutional investors must register in advance to participate. Formed from a spin-off of Merck (NYSE: MRK), Organon focuses on women's health with over 60 medicines and products, pursuing collaboration with biopharmaceutical innovators.

JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), will release its third quarter 2021 financial results on November 11, 2021, prior to the company’s webcast and conference call scheduled for 8:30 a.m. ET.

Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/. A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website.

Institutional investors and analysts interested in participating in the call must register in advance by clicking on this link: http://www.directeventreg.com/registration/event/2594964. Following registration, participants will receive a confirmation email containing details on how to join the conference call, including dial-information and a unique passcode and registrant ID. Pre-registration will allow participants to bypass an operator and be placed directly into the call.

About Organon

Organon is a global healthcare company formed through a spin-off from Merck, (NYSE: MRK), known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health, including business development like recently acquired Alydia Health, a medical device company focused on treating postpartum hemorrhage. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey.

For more information, visit http://www.organon.com and connect with us on LinkedIn and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211028005142/en/

Media Contacts:

Karissa Peer

(614) 314-8094

Kate Vossen

(732) 675-8448

Investor Contacts:

Jennifer Halchak

(201) 275-2711

Edward Barger

(267) 614-4669

Source: Organon & Co.

FAQ

When is Organon's third quarter 2021 financial results release?

Organon will release its third quarter 2021 financial results on November 11, 2021.

How can I access Organon's financial results conference call?

You can access the live conference call via the Organon website at 8:30 a.m. ET on November 11, 2021.

What is Organon's focus as a company?

Organon focuses on improving women's health, offering a portfolio of over 60 medicines.

What is the relationship between Organon and Merck?

Organon was formed through a spin-off from Merck (NYSE: MRK) to dedicate efforts towards women's health.

Is there a replay available for the Organon conference call?

Yes, a replay of the webcast will be available approximately two hours after the live event.